Arantxazu
Isla Ruiz
Hospital Universitario Araba
Vitoria, EspañaPublications in collaboration with researchers from Hospital Universitario Araba (39)
2024
2023
-
Ceftaroline and Avibactam Removal by Continuous Renal Replacement Therapies: An in vitro Study
Blood Purification, Vol. 52, Núm. 5, pp. 464-473
-
Pharmacokinetic/Pharmacodynamic Analysis of Oral Calcium Fosfomycin: Are Urine Levels Sufficient to Ensure Efficacy for Urinary Tract Infections?
Pharmaceutics, Vol. 15, Núm. 4
2022
-
Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study
Journal of Intensive Care, Vol. 10, Núm. 1
2021
-
Evaluation of the adequacy of the antimicrobial therapy of invasive Haemophilus influenzae infections: A pharmacokinetic/pharmacodynamic perspective
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 2, pp. 65-71
-
Pharmacokinetic/pharmacodynamic evaluation of the antimicrobial therapy of pneumococcal invasive disease in adults in post-PCV13 vaccine period in Madrid, Spain
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 40, Núm. 10, pp. 2145-2152
-
Population pharmacokinetics of levetiracetam and dosing evaluation in critically ill patients with normal or augmented renal function
Pharmaceutics, Vol. 13, Núm. 10
-
Pseudomonas aeruginosa susceptibility in spain: Antimicrobial activity and resistance suppression evaluation by pk/pd analysis
Pharmaceutics, Vol. 13, Núm. 11
-
Quantification of ceftaroline in human plasma using high‐performance liquid chromatography with ultraviolet detection: Application to pharmacokinetic studies
Pharmaceutics, Vol. 13, Núm. 7
2020
-
Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective
International Journal of Infectious Diseases, Vol. 93, pp. 329-338
-
Novel population pharmacokinetic model for linezolid in critically ill patients and evaluation of the adequacy of the current dosing recommendation
Pharmaceutics, Vol. 12, Núm. 1
2019
-
Application of pharmacokinetic/pharmacodynamic analysis to evaluate the adequacy of antimicrobial therapy for pediatric acute otitis media in Spain before and after the introduction of the PCV7 vaccine
Revista Espanola de Quimioterapia, Vol. 32, Núm. 2, pp. 121-129
-
Pharmacokinetic/pharmacodynamic analysis as a tool for surveillance of the activity of antimicrobials against Pseudomonas aeruginosa strains isolated in critically ill patients
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 6, pp. 380-386
-
Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment
Journal of Critical Care, Vol. 50, pp. 69-76
-
Susceptibility of Pseudomonas aeruginosa and antimicrobial activity using PK/PD analysis: an 18-year surveillance study
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 10, pp. 626-633
2018
-
Augmented Renal Clearance in Critically Ill Patients: A Systematic Review
Clinical Pharmacokinetics, Vol. 57, Núm. 9, pp. 1107-1121
-
Population pharmacokinetics of daptomycin in critically ill patients
International Journal of Antimicrobial Agents, Vol. 52, Núm. 2, pp. 158-165
2016
-
Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 35, Núm. 3, pp. 511-519
2015
-
Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function
International Journal of Antimicrobial Agents, Vol. 45, Núm. 4, pp. 399-405
-
Population pharmacokinetic models for cefuroxime and metronidazole used in combination as prophylactic agents in colorectal surgery: Model-based evaluation of standard dosing regimens
International Journal of Antimicrobial Agents, Vol. 45, Núm. 5, pp. 504-511